MYRIAD GENETICS INC Annual Report - A Deep Dive into Their 2025 Performance

Considering an investment in Myriad Genetics? This summary breaks down their latest annual report for the fiscal year ending December 31, 2025. We translate complex financial details into clear, actionable insights, helping you understand the company's performance and its potential fit for your portfolio.

Myriad Genetics (Nasdaq: MYGN) stands as a prominent provider of genetic testing and precision medicine solutions. The company specializes in tests for hereditary cancer, women's health (such as prenatal screening), and mental health (including pharmacogenomics, which helps tailor medication based on genetic makeup). Myriad aims to provide patients and physicians with practical genetic insights to improve health outcomes.

As of December 31, 2025, Myriad reported a market capitalization of approximately $494 million, with about 93.5 million shares of common stock outstanding. This places Myriad as a mid-sized competitor in the genetic testing market.

Financial Performance: A Mixed Bag in 2025

In the fiscal year ended December 31, 2025, Myriad Genetics generated total revenue of $620 million. This represents a modest 3% increase from $602 million in the previous year. Increased test volumes in their women's health and pharmacogenomics segments primarily drove this growth, though pricing pressures in hereditary cancer testing partially offset it.

Despite revenue growth, the company encountered profitability challenges. Myriad reported a net loss of $35 million, or ($0.37) per diluted share, a significant increase from the $20 million net loss, or ($0.21) per diluted share, in 2024. Increased investments in research and development (R&D) for new pipeline products and higher selling, general, and administrative (SG&A) expenses for commercial expansion primarily drove this wider loss.

Financial Health: Managing Cash and Debt

As of December 31, 2025, Myriad reported cash and cash equivalents of $110 million. This marks a decrease from $145 million at the end of 2024, reflecting operational losses and R&D expenditures. Total debt remained at $75 million, primarily from a revolving credit facility. While the company possesses sufficient liquidity for immediate operations, continued cash usage will require close monitoring. Its current ratio of 1.8x indicates a healthy capacity to meet short-term financial commitments.

Key Wins and Challenges in 2025 (Management Discussion)

Major Wins:

• Product Launches: Myriad launched two new genetic tests: "Myriad Harmony Plus" for expanded prenatal screening in Q2 2025, and "GeneSight Psychotropic 2.0" with enhanced AI-driven insights in Q4 2025.
• Strategic Partnership: The company formed a key collaboration with a major academic medical center, integrating its genetic testing into routine clinical practice and boosting market penetration.
• Operational Efficiency: Myriad implemented cost-saving measures in laboratory operations, resulting in a 2% improvement in gross margin for specific test panels.

Challenges:

• Reimbursement Pressures: Myriad continued to face difficulties securing favorable reimbursement rates for certain hereditary cancer tests, which affected average selling prices.
• Intense Competition: The company encountered aggressive competition from both established players and new entrants in the genetic testing market, especially in the hereditary cancer and women's health segments.
• R&D Investment Lag: Despite heavy R&D investment, the time-to-market for new, high-margin products proved longer than anticipated, contributing to current profitability issues.

Competitive Landscape and Strategy

Myriad operates within a highly competitive and rapidly evolving industry. Key competitors include Invitae, Exact Sciences, and various academic institutions. In 2025, Myriad's strategy centered on diversifying its product portfolio beyond hereditary cancer, with substantial investments in women's health and pharmacogenomics. The company aims to leverage its established clinical relationships and data analytics capabilities to differentiate its offerings and gain market share in these expanding areas. Myriad also emphasized improving patient access through telehealth partnerships.

Risks to Consider

Investors should be aware of several key risks:

• Reimbursement Uncertainty: Changes in healthcare policy or insurer coverage could significantly impact Myriad's revenue and profitability.
• Technological Obsolescence: The rapid pace of innovation in genetic sequencing could make existing tests less competitive.
• Regulatory Scrutiny: Increased oversight from the FDA or other regulatory bodies might lead to higher compliance costs or restrictions on product offerings.
• Data Privacy: Handling sensitive genetic information exposes the company to substantial data security and privacy risks.
• Competition: Aggressive pricing or superior product development by competitors could erode Myriad's market share.

Future Outlook

For 2026, Myriad Genetics anticipates continued R&D investment, focusing on bringing two new oncology-focused diagnostic tests to market by late 2026. The company projects revenue growth of 5-7% for the upcoming fiscal year. New product launches and expanded commercial reach for its women's health portfolio will drive this growth. Myriad expects to achieve positive adjusted EBITDA by the second half of 2026, as R&D investments begin to yield commercial returns and operational efficiencies take hold. Myriad's long-term strategy centers on becoming a leader in personalized medicine across multiple disease states, expanding beyond its traditional cancer focus.

In summary, Myriad Genetics navigated a challenging 2025, achieving modest revenue growth but experiencing increased losses due to strategic investments. While the company faces significant competition and reimbursement hurdles, its focus on portfolio diversification and R&D pipeline development positions it for potential future growth, albeit with inherent risks in this dynamic industry.